NCT00375752 - Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

June 1, 2006

Primary Completion Date

December 16, 2010

Study Completion Date

December 16, 2010

Conditions

Breast Neoplasms

Interventions

DRUG

Letrozole

2.5 mg.tablet.

DRUG

Zolendronic Acid

4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)

Trial Locations (27)

10365

Novartis Investigative Site, Berlin

22457

Novartis Investigative Site, Hamburg

29223

Novartis Investigative Site, Celle

30625

Novartis Investigative Site, Hanover

31785

Novartis Investigative Site, Hamelin

45147

Novartis Investigative Site, Essen

45276

Novartis Investigative Site, Essen

50924

Novartis Investigative Site, Cologne

63450

Novartis Investigative Site, Hanau

66538

Novartis Investigative Site, Neunkirchen

71032

Novartis Investigative Site, Böblingen

73730

Novartis Investigative Site, Esslingen am Neckar

74064

Novartis Investigative Site, Heilbronn

79106

Novartis Investigative Site, Freiburg im Breisgau

79618

Novartis Investigative Site, Rheinfelden

81377

Novartis Investigative Site, München

81545

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

85560

Novartis Investigative Site, Ebersberg

87439

Novartis Investigative Site, Kempten

89070

Novartis Investigative Site, Ulm

89703

Novartis Investigative Site, Ulm

90766

Novartis Investigative Site, Fürth

91052

Novartis Investigative Site, Erlangen

92224

Novartis Investigative Site, Amberg

06110

Novartis Investigative Site, Halle

04277

Novartis Investigative Site, Leipzig